





## Disclosures of Potential Conflicts of Interest

No potential conflicts of interest were disclosed.

## Acknowledgments

We thank Ute E. Burkhardt for helpful suggestions to the manuscript.

## References

1. Heemskerck B, Kvistborg P, Schumacher TN. The cancer antigenome. *EMBO J* 2013; 32:194-203; PMID:23258224; <http://dx.doi.org/10.1038/emboj.2012.333>
2. Hacohen N, Fritsch EF, Carter TA, Lander ES, Wu CJ. Getting personal with neoantigen-based therapeutic cancer vaccines. [*Cancer Immunology at the Crossroads*]. *Cancer Immunol Res* 2013; 1:11-5; PMID:24777245; <http://dx.doi.org/10.1158/2326-6066.CIR-13-0022>
3. Robbins PF, Lu YC, El-Gamil M, Li YF, Gross C, Gartner J, Lin JC, Teer JK, Cliften P, Tycksen E, et al. Mining exomic sequencing data to identify mutated antigens recognized by adoptively transferred tumor-reactive T cells. *Nat Med* 2013; 19:747-52; PMID:23644516; <http://dx.doi.org/10.1038/nm.3161>
4. Wick DA, Webb JR, Nielsen JS, Martin SD, Kroeger DR, Milne K, Castellarin M, Twumasi-Boateng K, Watson PH, Holt RA, et al. Surveillance of the tumor mutanome by T cells during progression from primary to recurrent ovarian cancer. *Clin Cancer Res* 2014; 20:1125-34; PMID:24323902; <http://dx.doi.org/10.1158/1078-0432.CCR-13-2147>
5. Gros A, Robbins PF, Yao X, Li YF, Turcotte S, Tran E, Wunderlich JR, Mixon A, Farid S, Dudley ME, et al. PD-1 identifies the patient-specific CD8<sup>+</sup> tumor-reactive repertoire infiltrating human tumors. *J Clin Invest* 2014; 124:2246-59; PMID:24667641; <http://dx.doi.org/10.1172/JCI73639>
6. Tran E, Turcotte S, Gros A, Robbins PF, Lu Y-C, Dudley ME, Wunderlich JR, Somerville RP, Hogan K, Hinrichs CS, et al. Cancer immunotherapy based on mutation-specific CD4<sup>+</sup> T cells in a patient with epithelial cancer. *Science* 2014; 344:641-5; PMID:24812403; <http://dx.doi.org/10.1126/science.1251102>
7. Fritsch EF, Rajasagi M, Ott PA, Brusica V, Hacohen N, Wu CJ. HLA-binding properties of tumor neoepitopes in humans. *Cancer Immunology Research* 2014.
8. van Rooij N, van Buuren MM, Philips D, Velds A, Toebes M, Heemskerck B, van Dijk LJ, Behjati S, Hilkmann H, El Atmioui D, et al. Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma. *J Clin Oncol* 2013; 31:e439-42; PMID:24043743; <http://dx.doi.org/10.1200/JCO.2012.47.7521>
9. Burkhardt UE, Hainz U, Stevenson K, Goldstein NR, Pasek M, Naito M, Wu D, Ho VT, Alonso A, Hammond NN, et al. Autologous CLL cell vaccination early after transplant induces leukemia-specific T cells. *J Clin Invest* 2013; 123:3756-65; PMID:23912587; <http://dx.doi.org/10.1172/JCI69098>
10. Rajasagi M, Shukla SA, Fritsch EF, Keskin DB, DeLuca D, Carmona E, Zhang W, Sougnez C, Cibulskis K, Sidney J, et al. Systematic identification of personal tumor-specific neoantigens in chronic lymphocytic leukemia. *Blood* 2014; 124:453-62; PMID:24891321; <http://dx.doi.org/10.1182/blood-2014-04-567933>
11. Brown SD, Warren RL, Gibb EA, Martin SD, Spinelli JJ, Nelson BH, Holt RA. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. *Genome Res* 2014; 24:743-50; PMID:24782321; <http://dx.doi.org/10.1101/gr.165985.113>